|
1.
|
|
16 p, 1.6 MB |
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer : results from the Spanish early access program
/
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid)) ;
García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Palmero, Ramón (Hospital Universitari de Bellvitge) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Bayona, Cristina (Hospital General Yague (Burgos)) ;
Rodríguez-Abreu, Delvys (Hospital Insular de Gran Canaria) ;
López-Brea, Marta (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Vicente, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Sánchez Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Majem, Margarita (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Diz, Pilar (Complejo Asistencial Universitario de León) ;
Gordo, Rocío (Roche Farma. S.A.) ;
Coca, Margarita (Roche Farma. S.A.) ;
de Castro, Javier (Hospital Universitario La Paz (Madrid))
This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive nonsmall-cell lung cancer (ALK+ NSCLC) according to data collected between November 2019 and October 2020 in 38 Spanish hospitals. [...]
2022 -  10.18632/oncotarget.28244
Oncotarget, Vol. 13 Núm. 1 (2022) , p. 812-827
|
|
|
2.
|
|
14 p, 1.3 MB |
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659)
/
Gordon, Leo I. (Northwestern University Feinberg School of Medicine) ;
Karmali, Reem (Northwestern University Feinberg School of Medicine) ;
Kaplan, Jason B. (Northwestern University Feinberg School of Medicine) ;
Popat, Rakesh (University College London) ;
Burris, Howard A. (Sarah Cannon Research Institute/Tennessee Oncology) ;
Ferrari, Silvia (Ospedale Papa Giovanni XXIII) ;
Madan, Sumit (Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA) ;
Patel, Manish R. (Florida Cancer Specialists/Sarah Cannon Research Institute) ;
Gritti, Giuseppe (Ospedale Papa Giovanni XXIII) ;
El-Sharkawi, Dima (Royal Marsden Hospital (Regne Unit)) ;
Chau, F. Ian (Royal Marsden Hospital (Regne Unit)) ;
Radford, John (University of Manchester) ;
de Oteyza, Jaime Pérez (Hospital Universitario HM Sanchinarro (Madrid)) ;
Zinzani, Pier Luigi (Università di Bologna) ;
Iyer, Swaminathan P. (University of Texas MD Anderson Cancer Center) ;
Townsend, William (University College London Hospitals) ;
Miao, Harry (Takeda Development Center Americas) ;
Proscurshim, Igor (Takeda Development Center Americas) ;
Wang, Shining (Takeda Development Center Americas) ;
Katyayan, Shilpi (Labcorp Drug Development (Estats Units d'Amèrica)) ;
Yuan, Ying (Takeda Development Center Americas) ;
Zhu, Jiaxi (Takeda Development Center Americas) ;
Stumpo, Kate (Takeda Development Center Americas) ;
Shou, Yaping (Takeda Development Center Americas) ;
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ;
Bosch José, Francesc Xavier 1947- (Universitat Autònoma de Barcelona)
We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of lymphoma patients, and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; including an expanded cohort not included in the initial report). [...]
2023 - 10.18632/oncotarget.28352
Oncotarget, Vol. 14 (january 2023) , p. 57-70
|
|
|
3.
|
|
20 p, 8.2 MB |
Acute telomere deprotection prevents ongoing BFB cycles and rampant instability in p16 INK4a -deficient epithelial cells
/
Bernal Martínez, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Moltó Abad, Marc (Hospital Universitari Vall d'Hebron) ;
Domínguez, Daniel (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Tusell Padrós, Laura (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Telomere dysfunction drives chromosome instability through endless breakage-fusion-bridge (BFB) cycles that promote the formation of highly rearranged genomes. However, reactivation of telomerase or ALT-pathway is required for genome stabilisation and full malignant transformation. [...]
2018 - 10.18632/oncotarget.25502
Oncotarget, Vol. 9 (june 2018) , p. 27151-27170
|
|
|
4.
|
|
13 p, 2.2 MB |
Monitoring EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
/
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mesia, Carles (Medical Oncology Department, Catalan Institute of Oncology - Hospital Duran i Reynalds, l'Hospitalet de Llobregat, Barcelona, Spain) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Roa, Diana (Hospital Universitari de Girona Doctor Josep Trueta) ;
Sais, Elia (Hospital Universitari de Girona Doctor Josep Trueta) ;
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Blanco, Remei (Consorci Sanitari de Terrassa. Departament d'Oncologia) ;
Sanchez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Villacorta, Claudia Rosa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Queralt, C. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Velarde, Jose María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (EGFR) mutations and acquired resistance (AR) to EGFR tyrosine kinase inhibitors due to EGFR -T790M mutation (T790M). [...]
2018 - 10.18632/oncotarget.25478
Oncotarget, Vol. 9 (june 2018) , p. 27074-27086
|
|
|
5.
|
|
13 p, 2.1 MB |
Increased plasma levels of galectin-1 in pancreatic cancer : potential use as biomarker
/
Martinez-Bosch, Neus (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Barranco, Luis E. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Orozco, Carlos A. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Moreno, Mireia (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Visa, Laura (Hospital del Mar (Barcelona, Catalunya)) ;
Iglesias, Mar (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Oldfield, Lucy (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ;
Neoptolemos, John P. (Department of General Surgery, University of Heidelberg, Heidelberg, Germany) ;
Greenhalf, William (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ;
Earl, Julie (Hospital Universitario Ramón y Cajal (Madrid)) ;
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Costello, Eithne (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ;
Navarro, Pilar (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. [...]
2018 - 10.18632/oncotarget.26034
Oncotarget, Vol. 9 (august 2018) , p. 32984-32996
|
|
|
6.
|
|
21 p, 2.1 MB |
Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants
/
Cullell, Natalia (Fundació per la Recerca Biomèdica i Social Mútua de Terrassa) ;
Carrera, Caty (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Muiño, Elena (Fundació per la Recerca Biomèdica i Social Mútua de Terrassa) ;
Torres, Nuria (Fundació per la Recerca Biomèdica i Social Mútua de Terrassa) ;
Krupinski, Jerzy (School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom) ;
Fernandez-Cadenas, Israel (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
Oral anticoagulants (OAs) are the recommended drugs to prevent cardiovascular events and recurrence in patients with atrial fibrillation (AF) and cardioembolic stroke. We conducted a literature search to review the current state of OAs pharmacogenomics, focusing on Genome Wide Association Studies (GWAs) in patients treated with vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). [...]
2018 - 10.18632/oncotarget.25579
Oncotarget, Vol. 9 (june 2018) , p. 29238-29258
|
|
|
7.
|
|
12 p, 1.6 MB |
Flow cytometric significance of cellular alkaline phosphatase activity in acute myeloid leukemia
/
G. Rico, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Junca, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ward, Michael D. (Thermo Fisher Scientific, Eugene, Oregon, USA) ;
Bradford, Jolene A. (Thermo Fisher Scientific, Eugene, Oregon, USA) ;
Petriz, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
In this prospective hospital-based cohort study that included 43 newly diagnosed patients with acute myeloid leukemia, flow cytometric cellular alkaline phosphatase (ALP) activity within primitive leukemic cells allowed us to identify two groups of patients at diagnosis according to the numbers of leukemic blasts expressing ≥ 12% of ALP+ cells (27 patients, Group A) and less than 12% of ALP+ cells (16 patients, Group B). [...]
2019 - 10.18632/oncotarget.27356
Oncotarget, Vol. 10 (december 2019) , p. 6969-6980
|
|
|
8.
|
|
8 p, 1.6 MB |
DNA methylation of MMPs and TIMPs in atherothrombosis process in carotid plaques and blood tissues
/
Gallego-Fabrega, Cristina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Cullell, Natalia (Institut d'Investigació Biomèdica Sant Pau) ;
Soriano-Tárraga, Carolina (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Carrera, Caty (Institut d'Investigació Biomèdica Sant Pau) ;
Torres-Aguila, Nuria P. (Institut d'Investigació Biomèdica Sant Pau) ;
Muiño, Elena (Institut d'Investigació Biomèdica Sant Pau) ;
Cárcel-Márquez, Jara (Institut d'Investigació Biomèdica Sant Pau) ;
de Moura, Manuel Castro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Sanlés, Alba (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Esteller, M. (Institució Catalana de Recerca i Estudis Avançats) ;
Elosua, Roberto (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Jiménez-Conde, Jordi (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Roquer, Jaume (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Montaner, Joan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Krupinski, Jerzy ;
Fernandez-Cadenas, Israel (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Background and Purpose: Polymorphisms and serum levels of Matrix Metalloproteinases (MMP) and Tissue Inhibitor of Metalloproteinases (TIMP) have been studied with regard to atheromatous plaques and ischemic stroke, while no studies of DNA methylation (DNAm) patterns of MMP or TIMP have been performed to that end. [...]
2020 - 10.18632/oncotarget.27469
Oncotarget, Vol. 11 (march 2020) , p. 905-912
|
|
|
9.
|
|
11 p, 3.2 MB |
Nerve-sparing versus non-nerve-sparing radical hysterectomy : surgical and long-term oncological outcomes
/
Gil-Moreno, Antonio 1965- (Hospital Universitari Vall d'Hebron) ;
Carbonell-Socias, Melchor (Hospital Universitari Vall d'Hebron) ;
Salicrú, Sabina (Hospital Universitari Vall d'Hebron) ;
Bradbury, Melissa (Hospital Universitari Vall d'Hebron) ;
García, Ángel (Hospital Universitari Vall d'Hebron) ;
Vergés, Ramona (Hospital Universitari Vall d'Hebron) ;
Puig, Oriol Puig (Hospital Universitari Vall d'Hebron) ;
Sánchez-Iglesias, José Luís (Hospital Universitari Vall d'Hebron) ;
Cabrera Díaz, Silvia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de la Torre, Javier (Hospital Universitari Vall d'Hebron) ;
Gómez-Hidalgo, Natalia R. (Hospital Universitari Vall d'Hebron) ;
Pérez-Benavente, Assumpció (Hospital Universitari Vall d'Hebron) ;
Díaz-Feijoo, Berta (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
There are controversies regarding the long-term oncological safety of preservation of pelvic innervation during radical hysterectomy (RH). This study aimed to analyze the feasibility and safety of nerve-sparing radical hysterectomy (NSRH) for cervical cancer compared with non-NSRH following 17 years of experience in a tertiary cancer referral center. [...]
2019 - 10.18632/oncotarget.27078
Oncotarget, Vol. 10 (july 2019) , p. 4598-4608
|
|
|
10.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
